文献速递关节外科创伤骨科

两期翻修髋关节置换术成功无需全身抗生素

Systemic antibiotics are not required for successful two-stage revision hip arthroplasty.
PubMed 文献 · Bone Joint J · 2023-05-01

本研究回顾性分析299例因假体周围感染接受两期翻修全髋关节置换术的患者,采用积极清创、骨水泥珠局部高浓度靶向抗生素及仅围手术期全身预防性抗生素的方案。再植入患者成功率为91%,包括未再植入者总成功率为86%,术后全身抗生素中位使用5天,较短疗程与较长疗程结局无显著差异。

要点

  • 两期翻修中积极清创联合局部高浓度靶向抗生素、不延长全身抗生素可获得高成功率。
  • 再植入患者成功率为91%,包括未再植入者总成功率为86%。
  • 术后全身抗生素≤48小时或≤5天与更长疗程相比结局无显著差异。

核心结论

  • 对于髋关节假体周围感染,一期翻修时积极手术清创并使用骨水泥珠局部高浓度靶向抗生素、不延长全身抗生素,可获得高成功率、负责任的抗生素管理和降低的住院成本。

研究设计与样本

  • 回顾性分析前瞻性收集的数据库,纳入因髋关节假体周围感染计划行两期翻修、符合MSIS 2013主要标准且随访至少5年的患者,共299例两期翻修全髋关节置换术(289例患者)。

主要发现

  • 299例中258例(86%)进行了二期手术,平均年龄68.1岁(范围28至92),中位随访10.7年(IQR 6.3至15.0)。
  • 再植入患者成功率为91%,包括未再植入者总成功率为86%。
  • 一期术后全身抗生素中位使用5天(IQR 5至9)。
  • 抗生素使用≤48小时(p=0.961)或≤5天(p=0.376)与更长疗程相比结局无显著差异。
  • 革兰阳性假体周围感染成功率87%,革兰阴性84%,混合革兰72%(p=0.098)。

关键数值与推荐

  • 假体周围感染诊断依据MSIS 2013主要标准,结局评估采用MSIS工作组结局报告工具。
  • 再植入患者成功率为91%,包括未再植入者总成功率为86%。
  • 术后全身抗生素中位使用5天(IQR 5至9)。
  • 抗生素使用≤48小时(p=0.961)或≤5天(p=0.376)与更长疗程相比结局无显著差异。
  • 革兰阳性假体周围感染成功率87%,革兰阴性84%,混合革兰72%(p=0.098)。

临床怎么用

  • 作者的研究理念是进行积极清创,并在骨水泥珠中使用高局部浓度靶向抗生素,全身仅使用预防性抗生素。
  • 作者认为该方案不延长全身抗生素,可提供高成功率、负责任的抗生素管理和降低的住院成本。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The duration of systemic antibiotic treatment following first-stage revision surgery for periprosthetic joint infection (PJI) after total hip arthroplasty (THA) is contentious. Our philosophy is to perform an aggressive debridement, and to use a high local concentration of targeted antibiotics in cement beads and systemic prophylactic antibiotics alone. The aim of this study was to assess the success of this philosophy in the management of PJI of the hip using our two-stage protocol. The study involved a retrospective review of our prospectively collected database from which we identified all patients who underwent an intended two-stage revision for PJI of the hip. All patients had a diagnosis of PJI according to the major criteria of the Musculoskeletal Infection Society (MSIS) 2013, a minimum five-year follow-up, and were assessed using the MSIS working group outcome-reporting tool. The outcomes were grouped into 'successful' or 'unsuccessful'. A total of 299 two-stage revision THAs in 289 patients met the inclusion criteria, of whom 258 (86%) proceeded to second-stage surgery. Their mean age was 68.1 years (28 to 92). The median follow-up was 10.7 years (interquartile range (IQR) 6.3 to 15.0). A 91% success rate was seen in those patients who underwent reimplantation, decreasing to 86% when including those who did not proceed to reimplantation. The median duration of postoperative systemic antibiotics following the first stage was five days (IQR 5 to 9). There was no significant difference in outcome between those patients who were treated with antibiotics for ≤ 48 hours (p = 0.961) or ≤ five days (p = 0.376) compared with those who were treated with longer courses. Greater success rates were seen for Gram-positive PJIs (87%) than for Gram-negative (84%) and mixed-Gram PJIs (72%; p = 0.098). Aggressive surgical debridement with a high local concentration of targeted antibiotics at the time of first-stage revision surgery for PJI of the hip, without prolonged systemic antibiotics, provides a high rate of success, responsible antibiotic stewardship, and reduced hospital costs.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Petrie MJ, Panchani S, Al-Einzy M, et al. Systemic antibiotics are not required for successful two-stage revision hip arthroplasty. Bone Joint J. 2023. PMID: 37121584. doi:10.1302/0301-620X.105B5.BJJ-2022-0373.R2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。